Jayne Toledano Miranda is CEO at Entera Bio Ltd. (ENTX). They have made 6 open-market trades across 2 companies since 2021, most recently 2026-07-14.
CIK 0001686530
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $123K since 2021, never a sale. Across 6 scored buys the stock is up 23.1% at ninety days, and 22.1 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ENTX | 774,142 | $2.4M |
| CMPX | 1,791,549 | $1.4M |
| DERM | 168,618 | $800K |
| NXGL | 1,819 | $8K |
| Total | $4.6M |
Shares reported on the most recent Form 4, priced at the 2026-07-16 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 50% | 67% |
| Avg Move | +1.3% | -1.1% | +23.1% |
| Alpha | +1.5% | -0.3% | +22.1% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ENTX | BUY | 2025-12-29 | 2025-12-30 | $1.81 | $20K | -19.9% | -25.5% | -49.0% |
| ENTX | BUY | 2023-12-22 | 2023-12-27 | $0.71 | $17K | +20.6% | +38.1% | +145.9% |
| ENTX | BUY | 2023-04-04 | 2023-04-06 | $1.01 | $30K | +0.0% | +1.1% | +1.1% |
| ENTX | BUY | 2022-11-11 | 2022-11-14 | $0.53 | $27K | +26.6% | +11.9% | +60.7% |
| ENTX | BUY | 2022-01-14 | 2022-01-19 | $2.79 | $19K | -11.9% | -19.6% | +13.5% |
| NXGL | BUY | 2021-12-27 | 2022-01-03 | $5.49 | $10K | -7.4% | -12.7% | -33.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.